What Does Wall Street Think About Corcept Therapeutics (CORT)?

Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the best stocks to buy with over 50% upside potential. Canaccord Genuity analyst Edward Nash maintained a Buy rating on Corcept Therapeutics Incorporated (NASDAQ:CORT) on October 21, setting a $140 price target. Why Corcept Therapeutics Incorporated (CORT) Crashed On Monday Similarly, H.C. Wainwright analyst Swayampakula Ramakanth also maintained a Buy rating on Corcept Therapeutics Incorporated (NASDAQ:CORT) on October 20, and set a $145 price ta ...